Characteristic | Sugammadex (n = 59) | Neostigmine (n = 61) |
---|---|---|
PACU | ||
 Direct ICU/HDU transfer | 2 (3.4) | 1 (1.6) |
 Airway management in PACU | 0 | 0 |
 Duration of PACU stay (h) | 1.2 (0.8–2.0) | 1.1 (0.7–1.6) |
Discharge destination from PACU | ||
 Ward | 50 (87.7) | 54 (90.0) |
 ICU/HDU | 7 (12.3) | 6 (10.0) |
Acceptability of protocol | ||
 Highly acceptable | 32 (56.1) | 25 (42.4) |
 Acceptable | 24 (42.1) | 27 (45.8) |
 Neutral | 0 (0.0) | 3 (5.1) |
 Unacceptable | 1 (1.8) | 3 (5.1) |
 Highly unacceptable | 0 (0.0) | 1 (1.7) |
Postoperative day 1 | ||
 PONV since PACU arrival | 26 (44.1) | 30 (49.2) |
 Anti-emetic since PACU arrival | 25 (42.4) | 34 (55.7) |
 QoR-15 | 101.2 (18.0) | 102.6 (14.5) |
 Change in QoR-15 (day 1 - preoperative) | −30.3 (21.0) | −34.3 (18.3) |
 EQ-5D-5L score | 0.4 (0.1–0.6) | 0.4 (0.1–0.5) |
 EQ-VAS score | 60.0 (50.0–80.0) | 70.0 (60.0–75.0) |
Hospital discharge | ||
 Unplanned ICU/HDU admission | 3 (5.1) | 2 (3.3) |
 Duration of hospital stay (days) | 5.1 (3.1–9.2) | 5.1 (3.2–8.2) |
 Primary outcome—adjudicated | 5 (8.5) | 5 (8.2) |
 Atelectasis | 5 (8.5) | 5 (8.2) |
Postoperative day 30 | ||
 Days alive and at home | 25.0 (19.0–27.0) | 24.0 (21.0–27.0) |
Postoperative 3 months | ||
 EQ-5D-5L score | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) |
 EQ-VAS score | 80.0 (65.0–86.0) | 80.0 (70.0–90.0) |
Frailty | ||
 Non-frail (CFS score = 1–4) | 55 (94.8) | 56 (96.6) |
 Frail (CFS score = 5–9) | 3 (5.2) | 2 (3.4) |